A High Alanine Aminotransferase/Aspartate Aminotransferase Ratio Determines Insulin Resistance and Metabolically Healthy/Unhealthy Obesity in a General Adult Population in Korea: The Korean National Health and Nutritional Examination Survey 2007–2010

Abstract

Aims Early identification of individuals with insulin resistance (IR) and metabolically unhealthy state can help prevent various diseases and improve quality of life. In this study, we investigated a possible marker of IR and metabolic health status, alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio, and aimed to confirm its feasibility in a large population study.

Methods A total of 16,371 adults from Korean National Health and Examination Survey were studied. Participants were divided into four groups according to their ALT/AST ratio quartiles. The homeostatic model assessment of insulin resistance level and proportion of people with IR, impaired fasting glucose, and undiagnosed type 2 diabetes were compared for each group. Receiver-operating characteristics (ROC) curve was also used to assess the usefulness of ALT/AST ratio to identify individuals with IR and metabolically unhealthy.

Results In the groups with higher ALT/AST ratio, HOMA-IR level, proportion of IR, and proportion of individuals with IFG or type 2 diabetes mellitus was higher than that in those with low ALT/AST ratio. When analyzed with other factors related to IR, the data showed that the ALT/AST ratio was an independent predictor of IR (odds ratio 1.363, 95% confidential interval 1.323–1.405, p<0.001). When ROC curve analysis was done, area under curve (AUC) for identifying individuals with IR was 0.634. In addition, metabolically unhealthy individuals showed significantly higher ALT/AST ratio than metabolically healthy individuals (0.9780 vs 0.8511, p<0.001).

Conclusions ALT/AST ratio was well-correlated with IR, IR-related conditions, and metabolic health status. This easily accessible method to estimate IR may facilitate the early screening of IR, which can result in prevention of IR-related morbid conditions.

Key words

Insulin sensitivity - Endocrinology - Prediction of diabetes - Screening

• References

• 1 Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003; 46: 3-19
• 2 Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem. 2009; 42: 1331-1346
• 3 Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761
• 4 Hawley JA. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab Res Rev 2004; 20: 383-393
• 5 Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-285
• 6 Kim JK, Kim YJ, Fillmore JJ. et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-446
• 7 Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes 2010; 1: 36-47
• 8 Kang B, Yang Y, Lee EY. et al. Triglycerides/glucose index is a useful surrogate marker of insulin resistance among adolescents. Int J Obes (Lond) 2017; 41: 789-792
• 9 He J, He S, Liu K. et al. The TG/HDL-C ratio might be a surrogate for insulin resistance in chinese nonobese women. Int J Endocrinol 2014; 2014: 105168
• 10 Kawamoto R, Kohara K, Kusunoki T. et al. Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Cardiovasc Diabetol. 2012; 11: 117
• 11 Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000; 85: 4426-4433
• 12 Bonnet F, Ducluzeau PH, Gastaldelli A. et al. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes. 2011; 60: 1660-1667
• 13 Gomez-Samano MA, Cuevas-Ramos D, Mehta R. et al. Association of Alanine Aminotransferase Levels (ALT) with the Hepatic Insulin Resistance Index (HIRI): A cross-sectional study. BMC Endocr Disord 2012; 12: 16
• 14 Wu P, Chen Q, Chen L. et al. Dose-Response relationship between alanine aminotransferase levels within the reference interval and metabolic syndrome in chinese adults. Yonsei medical journal 2017; 58: 158-164
• 15 Stefan N, Haring H, Schulze M. Metabolically healthy obesity: The low-hanging fruit in obesity treatment?. Lancet Diabetes Endocrinol 2018; 6: 249-258
• 16 Stefan N, Schick F, Haring H. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017; 26: 292-300
• 17 Organization WH. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000
• 18 Kwon SS, Lee SG, Lee YH. et al. Homeostasis model assessment of insulin resistance in a general adult population in Korea: additive association of sarcopenia and obesity with insulin resistance. Clin Endocrinol (Oxf) 2017; 86: 44-51
• 19 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223
• 20 Laakso M. How good a marker is insulin level for insulin resistance?. Am J Epidemiol 1993; 137: 959-965
• 21 Marcovina S, Bowsher RR, Miller WG. et al. Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup. Clin Chem. 2007; 53: 711-716
• 22 Song Y, Manson JE, Tinker L. et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: The Women’s Health Initiative Observational Study. Diabetes Care. 2007; 30: 1747-1752
• 23 Haffner SM, Kennedy E, Gonzalez C. et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996; 19: 1138-1141
• 24 Ikeda Y, Suehiro T, Nakamura T. et al. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J. 2001; 48: 81-86
• 25 Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX. et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 2013; 13: 47
• 26 Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX. et al. Insulin resistance index (HOMA-IR) levels in a general adult population: Curves percentile by gender and age. The EPIRCE study. Diabetes Res Clin Pract 2011; 94: 146-155
• 27 Ioannou GN, Bryson CL, Boyko EJ. Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. J Diabetes Complications 2007; 21: 363-370
• 28 Yamada C, Mitsuhashi T, Hiratsuka N. et al. Optimal reference interval for homeostasis model assessment of insulin resistance in a Japanese population. J Diabetes Investig 2011; 2: 373-376
• 29 Felig P. The glucose-alanine cycle. Metabolism. 1973; 22: 179-207
• 30 Yamada C, Kondo M, Kishimoto N. et al. Association between insulin resistance and plasma amino acid profile in non-diabetic Japanese subjects. J Diabetes Investig 2015; 6: 408-415
• 31 Yamakado M, Tanaka T, Nagao K. et al. Plasma amino acid profile is associated with visceral fat accumulation in obese Japanese subjects. Clin Obes 2012; 2: 29-40
• 32 Lakka TA, Lakka HM, Salonen R. et al. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis. 2001; 154: 497-504
• 33 Karelis AD, St-Pierre DH, Conus F. et al. Metabolic and body composition factors in subgroups of obesity: What do we know?. J Clin Endocrinol Metab 2004; 89: 2569-2575
• 34 McLaughlin T, Abbasi F, Lamendola C. et al. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007; 167: 642-648